Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Baricitinib to Preserve Beta Cell Function in Newly Diagnosed Type 1 Diabetes
jRCT2031260417Phase 3Not yet recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Aug 2026
- Modality
- Small Molecules, Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, double-blind trial in diabetes mellitus type 1 (T1D) comparing Baricitinib with Placebo (2 arms). Primary endpoint: Change from Baseline in C-peptide Area Under the Curve (AUC). Planned start Aug 2026; status: not yet recruiting.
02
Drugs
baricitinib
03
Conditions
diabetes mellitus type 1 (T1D)
Beyond the preview
Go deeper on jRCT2031260417.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031260417.